A Phase II Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia
Status:
Not yet recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, placebo-controlled, multicenter study to evaluate the
safety and efficacy of AK102 in patients with Hypercholesterolemia Patients at Very High or
High Risk of Cardiovascular Disease .
The primary objective of this study is to evaluate the efficacy of AK102 in patients with
Hypercholesterolemia Patients at Very High or High Risk of Cardiovascular Disease .
Phase:
Phase 2
Details
Lead Sponsor:
Akeso
Collaborators:
AD Pharmaceuticals Co., Ltd. AD Pharmaceuticals Co., Ltd. (Guangzhou)